Ignite Creation Date:
2025-12-24 @ 10:09 PM
Ignite Modification Date:
2026-05-10 @ 9:12 AM
Study NCT ID:
NCT04783935
Status:
COMPLETED
Last Update Posted:
2025-01-22
First Post:
2021-03-03
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Extension to the MAGNIFY MS Trial on Mavenclad® (Magnify MS Extension)
Sponsor:
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Multiple Sclerosis | View |